Novo talks up drug launches in effort to win back investors
At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.